David T. Huang

David T. Huang

Auto-generated profile, based on publicly available information

David T. Huang

University of Rochester Medical Center

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 May 2007 in Journal of Cardiovascular Electrophysiology
Verified
Journal Article
Closed access
PDF file
DHDavid T. Huang
David T. Huang
HSHenry W. Sesselberg
Henry W. Sesselberg
SMSCOTT McNITT
SCOTT McNITT
KNKatia Noyes
Katia Noyes
MAMark L. Andrews
Mark L. Andrews
FGfor the MADIT‐II Research Group
for the MADIT‐II Research Group

10 August 2011 in Journal of Cardiovascular Electrophysiology
Verified
Journal Article
Closed access
PDF file
JPJustin Penn
Justin Penn
IGIlan Goldenberg
Ilan Goldenberg
AMArthur J. Moss
Arthur J. Moss
SMSCOTT McNITT
SCOTT McNITT
WZWojciech Zareba
Wojciech Zareba
FIfor the MADIT‐CRT Trial investigators
for the MADIT‐CRT Trial investigators

1 November 2008 in Progress in Cardiovascular Diseases
Verified
Journal Article
Closed access
DHDavid T. Huang
David T. Huang
DTDarren Traub
Darren Traub

12 November 2019 in European Heart Journal
Verified
Journal Article
Closed access
IGIlan Goldenberg
Ilan Goldenberg
DHDavid T Huang
David T Huang
JNJens Cosedis Nielsen
Jens Cosedis Nielsen
Multiple randomized multicentre clinical trials have established the role of the implantable cardioverter-defibrillator (ICD) as the mainstay in the treatment of ventricular tachyarrhythmias and sudden cardiac death (SCD) prevention. These trials have focused mainly on heart failure patients with advanced left ventricular dysfunction and were mostly conducted two decades ago, whereas a more recent trial has provided conflicting results. Therefore, much remains to be determined on how best to balance the identification of patients at high risk of SCD together with who would benefit most from ICD implantation in a contemporary setting. Implantable cardioverter-defibrillators have also evolved from the simple, defibrillation-only devices implanted surgically to more advanced technologies of multi-chamber devices, with physiologic bradycardic pacing, including cardiac resynchronization therapy, atrial and ventricular therapeutic pacing algorithms, and subcutaneous ICDs. These multiple options necessitate individualized approach to device selection and programming. This review will focus on the current knowledge on selection of patients for ICD treatment, device selection and programming, and future directions of implantable device therapy for SCD prevention.

28 July 2023 in Annals of Noninvasive Electrocardiology
Verified
Journal Article
Open access
DHDavid T. Huang
David T. Huang
IGIgor Gosev
Igor Gosev
KWKatherine L. Wood
Katherine L. Wood
HVHima Vidula
Hima Vidula
WSWilliam Stevenson
William Stevenson
IGIlan Goldenberg
Ilan Goldenberg
Background: The use of a Left Ventricular Assist Device (LVAD) in patients with advanced heart failure refractory to optimal medical management has progressed steadily over the past two decades. Data have demonstrated reduced LVAD efficacy, worse clinical outcome, and higher mortality for patients who experience significant ventricular tachyarrhythmia (VTA). We hypothesize that a novel prophylactic intra‐operative VTA ablation protocol at the time of LVAD implantation may reduce the recurrent VTA and adverse events postimplant.Methods: We designed a prospective, multicenter, open‐label, randomized‐controlled clinical trial enrolling 100 patients who are LVAD candidates with a history of VTA in the previous 5 years. Enrolled patients will be randomized in a 1:1 fashion to intra‐operative VTA ablation (n = 50) versus conventional medical management (n = 50) with LVAD implant. Arrhythmia outcomes data will be captured by an implantable cardioverter defibrillator (ICD) to monitor VTA events, with a uniform ICD programming protocol. Patients will be followed prospectively over a mean of 18 months (with a minimum of 9 months) after LVAD implantation to evaluate recurrent VTA, adverse events, and procedural outcomes. Secondary endpoints include right heart function/hemodynamics, healthcare utilization, and quality of life.Conclusion: The primary aim of this first‐ever randomized trial is to assess the efficacy of intra‐operative ablation during LVAD surgery in reducing VTA recurrence and improving clinical outcomes for patients with a history of VTA.

1 January 2024 in Circulation: Arrhythmia and Electrophysiology
Verified
Journal Article
Closed access
MCMichael J. Cutler
Michael J. Cutler
LELee L. Eckhardt
Lee L. Eckhardt
EKElizabeth S. Kaufman
Elizabeth S. Kaufman
Elena ArbeloElena Arbelo
Elena Arbelo
EBElijah R. Behr
Elijah R. Behr
AWArthur A.M. Wilde
Arthur A.M. Wilde
Although there is consensus on the management of patients with Brugada Syndrome with high risk for sudden cardiac arrest, asymptomatic or intermediate-risk patients present clinical management challenges. This document explores the management opinions of experts throughout the world for patients with Brugada Syndrome who do not fit guideline recommendations. Four real-world clinical scenarios were presented with commentary from small expert groups for each case. All authors voted on case-specific questions to evaluate the level of consensus among the entire group in nuanced diagnostic and management decisions relevant to each case. Points of agreement, points of controversy, and gaps in knowledge are highlighted.